← Oncology Approval Tracker

FDA DECISION ·

Avgemsi

gemcitabine · Avyxa Holdings

FDA approvalNew formulationOvarian, breast, lung and pancreatic cancers
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For advanced ovarian cancer relapsing at least 6 months after platinum with carboplatin; first-line metastatic breast cancer after failed adjuvant anthracycline therapy unless contraindicated, with paclitaxel; first-line inoperable locally advanced or metastatic NSCLC with cisplatin; and locally advanced or metastatic pancreatic adenocarcinoma in first-line use or after prior fluorouracil.

LAMPGEN ANALYSIS

Why it matters

A separate 505(b)(2) gemcitabine injection approval covers four established tumor settings with distinct regimens.

What research teams should watch

Check the exact formulation, vial preparation instructions, and the partner treatment and schedule required for each indication.

PRIMARY RECORDS

Sources